US FDA Doesn’t Want ANDAs With Facilities Not Ready For Inspection Even Though It Can Accept Them

 
• By Derrick Gingery
generic drugs
One of the priorities in GDUFA III is to reduce the number of assessment cycles needed to gain approval. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics